ASCEND-X Platform · AI/ML × Neuroimmunology
Antibody intelligence,
ascending.
Calysas Therapeutics is developing a novel generation of targeted therapeutics for neurodegenerative disease, powered by NeuroImmunomics™ at Time Zero.
The questions that drive us
What if neurodegeneration were detectable and treatable, prior to the onset of clinical symptoms?
What if the human immune response carries the code for identifying and treating these diseases?
What if these discoveries unlock a breakthrough generation of precision neurotherapeutics?
Vision
Reimagine the treatment of brain injury and neurodegenerative disease through a deeper understanding of human biology.
Precision approach
One platform. Human data in, precision medicines out.
Human data are decoded using the proprietary MOSAIC method, with clinical metadata overlay, and purpose-built, proprietary AI/ML — to rapidly identify novel drug targets, paired predictive biomarkers, and precision neurotherapeutics.
Human immune signal
Patient-derived antibody records of brain injury.
MOSAIC screen
Proprietary decoding of immune biology.
Clinical metadata
Overlay of real-world clinical context.
Proprietary AI/ML
Purpose-built models surface targets & biomarkers.
Novel drug targets
Paired predictive biomarkers
Precision neurotherapeutics
Initial focus
70k+
Americans die from TBI each year. No disease-modifying therapies exist.
A new generation of targeted therapies designed to address the complex biology of neurodegenerative disease. Our development strategy pairs therapeutic candidates with predictive biomarkers, enabling matching of the right treatment to the right patient.
Expansion — Therapeutics for neurodegenerative conditions such as CTE, dementias, and parkinsonism.